FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2557412097> ?p ?o ?g. }

• W2557412097 endingPage "3371" @default.
• W2557412097 startingPage "3371" @default.
• W2557412097 abstract "Abstract Smoldering multiple myeloma (SMM) is an asymptomatic plasma cell disorder whose risk of progression to symptomatic MM (MM) is highly variable. Therefore, the identification of predictors of progression into MM is a relevant end point. Several markers (serum M protein, percentage of bone marrow plasma cells, free light chain, FLC, ratio, immunophenotyping of aberrant plasma cells and focal lesions, FLs at MRI) have already been established to identify sub-groups of SMM patients (pts) with a highest risk of progression into MM. Among imaging methods, FDG-PET/CT is a reliable technique for assessing early skeletal involvement and for predicting outcomes at the onset of MM. However, no data are available regarding the impact of PET/CT FLs in SMM on time to progression (TTP) into symptomatic disease. To address this issue, we prospectively studied pts with a suspected diagnosis of SMM with FDG-PET/CT. A cohort of 73 pts, with a median age of 61 years old (range 27-83) and a confirmed diagnosis of SMM, followed for a median of 2.2 years, is herein reported. By study design, all the pts were studied with PET/CT at baseline. Bone marrow involvement was described as negative, diffuse or focal. The number of FLs, as well as size and associated standardized uptake values (SUV) were recorded. For each FL, the presence of eventual underlying osteolytic lesion was investigated by the CT part of the scan; pts with osteolytic lesions were excluded from the present study, as they were considered as having symptomatic MM. Follow-up took place every 3-4 months and included clinical history, serum and urine markers and PET/CT plus axial MRI for occurrence of symptoms or an increase in M component. Progression to MM was defined by the presence of CRAB features. Skeletal progression was defined by the appearance of one or more sites of osteolytic bone destruction, pathological fractures and/or soft masses at PET/CT or MRI. The start of systemic therapy was defined as the date of event for the analysis of TTP. Baseline patient characteristics were as follows: 83% had IgG isotype, 8% IgA and 9% BJ, with a median M component of 2.5 g/dL; 70% had ISS stage I, 23% stage II and 7% stage III. Median plasma cell involvement on bone marrow (BMPC) was 30% (range 5-100%), with 16% of the pts having more than 60% BMPC. The median serum involved/uninvolved FLC ratio was 14.39 (range 1.28-2255), with 11% of the pts presenting with a ratio ≥ 100. PET/CT was negative in 64/73 pts (88%) and positive in 9/73 (12%) of them; 5 pts had 1 FLs, 1 pt 2 FLs, 2 pts more than 3 FLs and 1 pt a diffuse bone marrow involvement. Median SUV max value was 4.45 (range 2.5-5.2). No significant differences between patients with positive or negative PET/CT were found regarding the other baseline characteristics. At the time of the present analysis, 63% of the pts remained in the asymptomatic phase while 37% of them progressed to MM, in a median time of 4 years, including 21% with skeleton involvement, with/without the appearance of other CRAB symptoms, and 16% with exclusive serological signs of progression. Sixty six per cent of the pts with positive PET/CT progressed to MM in comparison to 33% of the pts with negative PET/CT (P = 0.034). The relative risk of progression of the pts with a positive PET/CT was 2.3 (95% CI 09.-5.9, P= 0.06). Moreover, the relative risk of skeletal progression was 4.0 (95% CI 1.3-12, P= 0.013), with a median TTP of 2.2 years for pts with positive PET/CT versus 7 years for those with negative PET/CT (figure 1). The probability of progression within 2 and 3 years for pts with positive PET/CT was 48% and 65%, respectively, in comparison to 32% and 42% for negative pts. In conclusion, approximately 10% of the pts with SMM have a positive PET/CT, mainly with few FLs, without underlying osteolytic lesion, with a low FDG uptake. PET/CT positivity significantly increased the risk of progression of SMM into active MM. PET/CT could become a new risk factor to define high risk SMM. A larger cohort of pts will be presented at the meeting. Further studies are warranted to find and optimal cut off point of FLs to capture the higher risk of progression at 2 year and to merge with other prognostic factors. Figure 1 Figure 1. Disclosures No relevant conflicts of interest to declare." @default.
• W2557412097 created "2016-12-08" @default.
• W2557412097 creator A5002485247 @default.
• W2557412097 creator A5013203709 @default.
• W2557412097 creator A5030245472 @default.
• W2557412097 creator A5036642940 @default.
• W2557412097 creator A5040474758 @default.
• W2557412097 creator A5051226797 @default.
• W2557412097 creator A5051368482 @default.
• W2557412097 creator A5055543156 @default.
• W2557412097 creator A5059967673 @default.
• W2557412097 creator A5060396380 @default.
• W2557412097 creator A5069443833 @default.
• W2557412097 creator A5071926851 @default.
• W2557412097 creator A5075195900 @default.
• W2557412097 creator A5083765582 @default.
• W2557412097 creator A5086604304 @default.
• W2557412097 creator A5087207800 @default.
• W2557412097 creator A5087857567 @default.
• W2557412097 date "2014-12-06" @default.
• W2557412097 modified "2023-09-28" @default.
• W2557412097 title "The Presence of FDG PET/CT Focal, Not Osteolytic, Lesion(s) Identifies a Sub-Group of Patients with Smoldering Multiple Myeloma with High-Risk of Progression into Symptomatic Disease" @default.
• W2557412097 doi "https://doi.org/10.1182/blood.v124.21.3371.3371" @default.
• W2557412097 hasPublicationYear "2014" @default.
• W2557412097 type Work @default.
• W2557412097 sameAs 2557412097 @default.
• W2557412097 citedByCount "3" @default.
• W2557412097 countsByYear W25574120972015 @default.
• W2557412097 crossrefType "journal-article" @default.
• W2557412097 hasAuthorship W2557412097A5002485247 @default.
• W2557412097 hasAuthorship W2557412097A5013203709 @default.
• W2557412097 hasAuthorship W2557412097A5030245472 @default.
• W2557412097 hasAuthorship W2557412097A5036642940 @default.
• W2557412097 hasAuthorship W2557412097A5040474758 @default.
• W2557412097 hasAuthorship W2557412097A5051226797 @default.
• W2557412097 hasAuthorship W2557412097A5051368482 @default.
• W2557412097 hasAuthorship W2557412097A5055543156 @default.
• W2557412097 hasAuthorship W2557412097A5059967673 @default.
• W2557412097 hasAuthorship W2557412097A5060396380 @default.
• W2557412097 hasAuthorship W2557412097A5069443833 @default.
• W2557412097 hasAuthorship W2557412097A5071926851 @default.
• W2557412097 hasAuthorship W2557412097A5075195900 @default.
• W2557412097 hasAuthorship W2557412097A5083765582 @default.
• W2557412097 hasAuthorship W2557412097A5086604304 @default.
• W2557412097 hasAuthorship W2557412097A5087207800 @default.
• W2557412097 hasAuthorship W2557412097A5087857567 @default.
• W2557412097 hasConcept C126322002 @default.
• W2557412097 hasConcept C126838900 @default.
• W2557412097 hasConcept C142724271 @default.
• W2557412097 hasConcept C196166836 @default.
• W2557412097 hasConcept C203014093 @default.
• W2557412097 hasConcept C2776364478 @default.
• W2557412097 hasConcept C2777910003 @default.
• W2557412097 hasConcept C2780007613 @default.
• W2557412097 hasConcept C2781156865 @default.
• W2557412097 hasConcept C2989005 @default.
• W2557412097 hasConcept C553184892 @default.
• W2557412097 hasConcept C71924100 @default.
• W2557412097 hasConceptScore W2557412097C126322002 @default.
• W2557412097 hasConceptScore W2557412097C126838900 @default.
• W2557412097 hasConceptScore W2557412097C142724271 @default.
• W2557412097 hasConceptScore W2557412097C196166836 @default.
• W2557412097 hasConceptScore W2557412097C203014093 @default.
• W2557412097 hasConceptScore W2557412097C2776364478 @default.
• W2557412097 hasConceptScore W2557412097C2777910003 @default.
• W2557412097 hasConceptScore W2557412097C2780007613 @default.
• W2557412097 hasConceptScore W2557412097C2781156865 @default.
• W2557412097 hasConceptScore W2557412097C2989005 @default.
• W2557412097 hasConceptScore W2557412097C553184892 @default.
• W2557412097 hasConceptScore W2557412097C71924100 @default.
• W2557412097 hasIssue "21" @default.
• W2557412097 hasLocation W25574120971 @default.
• W2557412097 hasOpenAccess W2557412097 @default.
• W2557412097 hasPrimaryLocation W25574120971 @default.
• W2557412097 hasRelatedWork W2005843898 @default.
• W2557412097 hasRelatedWork W2152727128 @default.
• W2557412097 hasRelatedWork W2165862110 @default.
• W2557412097 hasRelatedWork W2204936399 @default.
• W2557412097 hasRelatedWork W2334622214 @default.
• W2557412097 hasRelatedWork W2369117338 @default.
• W2557412097 hasRelatedWork W2407303774 @default.
• W2557412097 hasRelatedWork W3032513420 @default.
• W2557412097 hasRelatedWork W4231807353 @default.
• W2557412097 hasRelatedWork W79788422 @default.
• W2557412097 hasVolume "124" @default.
• W2557412097 isParatext "false" @default.
• W2557412097 isRetracted "false" @default.
• W2557412097 magId "2557412097" @default.
• W2557412097 workType "article" @default.